HIMS

Hims & Hers Health

$28.27

+10.21%
May 8, 2026
Bobby Quantitative Model
Hims & Hers Health, Inc. is a direct-to-consumer telehealth platform that connects patients with healthcare providers to offer treatment and products for conditions including erectile dysfunction, hair loss, skincare, mental health, and weight loss. The company operates as a digital-first disruptor in the healthcare sector, leveraging its integrated platform of provider networks, electronic records, and pharmacy fulfillment to serve over 2 million subscribers without accepting insurance. The current investor narrative is dominated by a dramatic strategic pivot, having recently resolved a major legal dispute with Novo Nordisk and secured a partnership to sell its weight-loss drugs, which has overshadowed concerns about weak guidance and fueled a significant stock price recovery from recent lows.

People also watch

Envista Holdings Corporation

Envista Holdings Corporation

NVST

Analysis
Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis
Johnson & Johnson

Johnson & Johnson

JNJ

Analysis
AbbVie

AbbVie

ABBV

Analysis
UnitedHealth Group

UnitedHealth Group

UNH

Analysis

HIMS 12-Month Price Forecast

Historical Price
Current Price $28.27
Average Target $28.27
High Target $32.5105
Low Target $24.0295

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Hims & Hers Health's 12-month outlook, with a consensus price target around $36.75 and implied upside of +30.0% versus the current price.

Average Target

$36.75

6 analysts

Implied Upside

+30.0%

vs. current price

Analyst Count

6

covering this stock

Price Range

$23 - $37

Analyst target range

Buy
1 (17%)
Hold
3 (50%)
Sell
2 (33%)

A limited set of six analysts provide coverage for the stock, indicating it is a mid-cap name with evolving institutional interest. The consensus sentiment is difficult to pinpoint precisely without explicit buy/hold/sell counts and an average target price in the data, but recent institutional rating actions show a notable shift: in March 2026, Citigroup upgraded from 'Sell' to 'Neutral', B of A Securities upgraded from 'Underperform' to 'Neutral', and Needham upgraded from 'Hold' to 'Buy', signaling a clear bullish inflection in analyst sentiment following the Novo Nordisk deal. The wide range of analyst revenue estimates for the upcoming period, from a low of $4.01 billion to a high of $5.26 billion, reflects high uncertainty and divergent views on the company's growth trajectory post-partnership; the high estimates likely assume successful integration and rapid scaling of the new weight-loss drug offering, while the low estimates may price in execution risks or competitive pressures.

Drowning in data?

Find the real signal!

HIMS Technical Analysis

The stock is in a deep, volatile downtrend over the past year, with a 1-year price change of -24.2%, significantly underperforming the SPY's +29.04% gain. As of the latest close at $27.41, the price is trading at approximately 39% of its 52-week range ($13.74 to $70.43), positioning it near the lower bound and suggesting it has been treated as a 'falling knife' but may now present a deep-value opportunity or signal fundamental distress. Recent momentum shows a sharp but volatile recovery, with a 1-month surge of +38.16% dramatically diverging from the negative longer-term trends, indicating a potential trend reversal or a powerful short-term catalyst, as seen in the price jump from around $15 in late February to over $30 in April. Key technical levels are clear, with major resistance at the 52-week high of $70.43 and immediate support at the 52-week low of $13.74; a sustained breakout above the recent April high near $31 would signal strengthening bullish conviction, while a breakdown below $13.74 would indicate a complete failure of the recent rally. The stock's extreme volatility is confirmed by a beta of 2.315, meaning it is over 130% more volatile than the market, which necessitates larger risk buffers for investors.

Beta

2.42

2.42x market volatility

Max Drawdown

-78.1%

Largest decline past year

52-Week Range

$14-$70

Price range past year

Annual Return

-45.0%

Cumulative gain past year

PeriodHIMS ReturnS&P 500
1m+45.8%+9.1%
3m+22.8%+6.8%
6m-31.1%+9.9%
1y-45.0%+30.5%
ytd-15.4%+8.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

HIMS Fundamental Analysis

Revenue growth remains robust but shows signs of sequential deceleration; Q4 2025 revenue was $617.8 million, representing a strong 28.4% year-over-year growth, however, this marks a slowdown from the 49% YoY growth seen in Q3 2025 ($599.0 million), indicating growth is still healthy but moderating as the company scales. The company is profitable on a net income basis, with Q4 2025 net income of $20.6 million and a net margin of 3.3%, but profitability has become more challenged compared to earlier quarters like Q1 2025 which had a net margin of 8.4%; gross margin remains high at 71.9% for the quarter, though it has compressed from 73.8% in Q3, reflecting potential pricing pressure or mix shifts. The balance sheet shows a leveraged but liquid position, with a debt-to-equity ratio of 2.34 indicating significant financial leverage, offset by a strong current ratio of 1.90 and positive annual free cash flow of $72.9 million (TTM), suggesting the company can service its obligations and fund some growth internally, though the high leverage amplifies risk in a downturn.

Quarterly Revenue

$617818000.0B

2025-12

Revenue YoY Growth

+0.28%

YoY Comparison

Gross Margin

+0.71%

Latest Quarter

Free Cash Flow

$72858000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Open an Account, get $2 TSLA now!

Valuation Analysis: Is HIMS Overvalued?

Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is extremely high at 56.9x, while the forward P/E is significantly lower at 19.9x, indicating the market is pricing in a substantial acceleration in earnings growth, likely driven by the recent strategic partnership and resolution of legal overhangs. Compared to sector averages, the stock's Price-to-Sales ratio of 3.11x is not directly comparable without a provided industry average, but its forward P/E of 19.9x suggests a growth premium, which may be justified if the company can successfully execute on its new weight-loss drug channel and return to higher profit margins. Historically, the current trailing P/E of 56.9x is below its own peak historical multiples seen in recent quarters (e.g., 89.5x at the end of Q4 2025) but remains elevated compared to its lows during periods of net losses, suggesting the market is still assigning a growth premium, albeit a reduced one following the significant price decline over the past six months.

PE

56.9x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range -68x~375x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

52.1x

Enterprise Value Multiple